KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial. PMID 41797062 · Eur J Surg Oncol · 2026-Apr The study is a feasibility trial evaluating a very low-calorie diet (non-drug intervention) before liver resection for liver neoplasms. It is not a Phase III or definitive randomized trial, and no time-to-event efficacy endpoints (e.g., OS, PFS) or Kaplan-Meier analyses are reported. The intervention is not drug-containing.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk factors for recurrence of vulvar high-grade squamous intra-epithelial lesions: long-term follow-up of the PITVIN Study (primary imiquimod vs surgery for vulvar intra-epithelial neoplasia). PMID 41791272 · Int J Gynecol Cancer · 2026-Apr The record describes a long-term follow-up of a Phase 3 randomized trial of imiquimod vs surgery for vulvar HSIL. While it meets criteria for oncology, human, randomized, Phase 3, and drug intervention, the efficacy endpoint is recurrence of a pre-cancerous lesion (HSIL), not a time-to-event endpoint for a malignant neoplasm (e.g., OS, PFS, DFS). Therefore, it does not meet the required primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm. The report is also a secondary analysis (long-term follow-up) rather than a primary efficacy report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine. PMID 41781546 · Nat Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Likelihood ratio test for the disease progression model to measure saved time in Alzheimer's disease. PMID 41773781 · Stat Methods Med Res · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker. PMID 41767204 · J Am Coll Emerg Physicians Open · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). PMID 41763966 · Ann Rheum Dis · 2026-Apr The study is a randomized Phase III trial of a drug (ozoralizumab, a TNF inhibitor) in rheumatoid arthritis, not a human malignant neoplasm. While it meets criteria for randomized, phase 3, human, drug intervention, and original result, it is excluded because it is non-oncology and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial. PMID 41763237 · Lancet Respir Med · 2026-Apr Study is a Phase III randomized trial in oncology with human participants and an original primary result, but it does not meet the core eligibility criteria because it lacks a primary/key time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) and its intervention is a medical device (IPC) combined with a procedure, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study. PMID 41763071 · J Anxiety Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Renal Flares and Health-Related Quality of Life Among Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from the LUNAR Phase 3 Clinical Trial. PMID 41761038 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical efficacy of Xiaotan Sanjie decoction in treating gastric cancer with peritoneal metastases: A study protocol for a randomized controlled trial. PMID 41756199 · Contemp Clin Trials Commun · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. PMID 41735092 · J Clin Lipidol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. PMID 41731117 · Br J Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. PMID 41730814 · Lancet Diabetes Endocrinol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy. PMID 41730506 · Diabetes Res Clin Pract · 2026-Apr The record describes a pharmacogenetic substudy of the FIELD trial. While the FIELD trial itself is a Phase III randomized trial of a drug (fenofibrate) with time-to-event efficacy endpoints, the specific study is not an oncology trial. Its primary outcomes are diabetic vascular complications and mortality; cancer-related mortality is only one of several secondary mortality endpoints analyzed in the context of a genetic variant. Therefore, it does not meet the core requirement of being a report on an oncology (human malignant neoplasm) clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The differential effects of social support on quality of life in head and neck cancer patients in the United States and China. PMID 41723882 · Eur J Oncol Nurs · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. PMID 41717679 · Hypertension · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. PMID 41714403 · Leukemia · 2026-Apr The record describes a translational/biomarker study (miR-29 in follicular lymphoma) that uses a published RCT (SWOG S0016) as a validation cohort for survival correlations. It is not a report of the original, formal, drug-containing, Phase III/IIIb or Phase II/III randomized trial's efficacy results. The drug intervention criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The "decompressing stoma - neoadjuvant Folfox chemotherapy - colectomy" strategy for non-metastatic obstructive colon cancer: A French retrospective multi-institutional case series. PMID 41713642 · Clin Res Hepatol Gastroenterol · 2026-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Effects of polymer oxygenated alginate dressings for healing skin graft donor areas: A phase III randomized controlled trial. PMID 41713054 · Burns · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Classic Hodgkin Lymphoma in the Older Adult: What's New? PMID 41708412 · Hematol Oncol Clin North Am · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical protocol for the K-3 trial: a single-center, patient-blinded, randomized clinical trial addressing anesthesiologic, oncological and patient recovery outcomes of standard flank approach vs supine approach for robot-assisted partial nephrectomy. PMID 41707608 · Surg Oncol · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Machine Learning to Predict Outcomes and Dosing Frequency With Aflibercept for Macular Edema Following Central Retinal Vein Occlusion. PMID 41705990 · Ophthalmic Surg Lasers Imaging Retina · 2026-Apr 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. PMID 41704058 · Br J Haematol · 2026-Apr The record describes a randomized, multicentre trial with a primary EFS endpoint and formal results, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Phase classification cannot be established from the abstract alone.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial. PMID 41702154 · Oral Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. PMID 41692019 · Lancet Respir Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial. PMID 41691937 · Neuromuscul Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial. PMID 41690405 · Radiother Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. PMID 41689889 · Lung Cancer · 2026-Apr The report is a subset analysis (Asian participants) of the MARIPOSA trial. While the analysis itself has formal results, it is not the primary report of the Phase III/definitive trial; it is a secondary/subgroup analysis. The original MARIPOSA trial is likely Phase III (based on drug names and standard trial design for approval), but the report's own metadata does not explicitly confirm the phase of the MARIPOSA trial itself. Therefore, phase3_or_definitive cannot be confirmed from this record alone.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes. PMID 41689888 · J Prev Alzheimers Dis · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial. PMID 41689868 · Urol Oncol · 2026-Apr The record is a randomized, oncology trial with drug intervention and key time-to-event endpoints (RFS, PFS) reported via Kaplan-Meier. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided information, which is a required criterion for eligibility. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY. PMID 41679125 · J Diabetes Complications · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ASO Visual Abstract: Health Care Utilization, Costs, and Cost-Effectiveness for Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomised Controlled, Phase 3, Superiority Trial. PMID 41670859 · Ann Surg Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy. PMID 41670693 · Naunyn Schmiedebergs Arch Pharmacol · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. PMID 41667130 · BJU Int · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials. PMID 41666849 · Lung Cancer · 2026-Apr The record is a secondary analysis of participation in biospecimen studies within two phase 3 lung cancer therapeutic trials. While the parent trials are oncology, human, randomized, phase 3, and drug-interventional, this specific publication does not report original trial efficacy results or any time-to-event endpoints. It focuses on factors associated with patient consent for biospecimen collection, making it a secondary/sociological analysis rather than a primary efficacy report eligible for Kaplan-Meier digitization.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins. PMID 41664920 · Circ Genom Precis Med · 2026-Apr 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial. PMID 41662856 · Lancet Gastroenterol Hepatol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study). PMID 41661417 · Int J Clin Oncol · 2026-Apr The study is an oncology, human, randomized trial with drug intervention and time-to-event endpoints (PFS, OS). However, the trial is explicitly described as an 'exploratory study' and no Phase III/IIIb or Phase II/III designation is provided in the title, abstract, or metadata. Phase cannot be inferred from the drug name or regimen comparison. Therefore, the critical phase3_or_definitive criterion is not established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study. PMID 41652222 · Br J Cancer · 2026-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata. PMID 41645877 · J Dermatol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial. PMID 41644383 · Int J Gynecol Cancer · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study. PMID 41641373 · Neurol Clin Pract · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Association between treatment-induced changes in the Kansas City Cardiomyopathy Questionnaire and clinical outcomes in chronic heart failure: a trial-level meta-regression analysis. PMID 41641158 · Int J Cardiol Heart Vasc · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index. PMID 41637791 · Breast · 2026-Apr This is a secondary analysis (prognostic biomarker validation) of two Phase III randomized trials (SOFT/TEXT). While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it does not represent a primary report of the trial's efficacy results for a drug-containing intervention. The abstract describes a reclassification of risk groups using a biomarker index, not the primary trial comparison of endocrine therapies.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). PMID 41633909 · Eur Urol Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PMID 41629425 · Nat Med · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial. PMID 41621679 · Radiother Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52. PMID 41611341 · Cancer Sci · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 3 Panel · risk unclear
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. PMID 41606119 · Nat Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer. PMID 41581361 · Breast · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 12 Panel · risk unclear